[SCHEDULE 13D/A] Atara Biotherapeutics, Inc SEC Filing
Amendment No. 1 to a Schedule 13D reports that a group of Panacea-related entities and James Huang together beneficially own 1,712,900 shares of Atara Biotherapeutics common stock, representing 20.0% of the 7,023,032 shares outstanding as of August 6, 2025. The position includes 307,900 warrants that are immediately exercisable but are subject to a contractual cap preventing exercise to the extent it would increase beneficial ownership above 19.99%, so the warrants cannot currently be exercised. Panacea Venture Healthcare Fund II, L.P. purchased 74,335 shares in open market transactions from July 17 through August 19, 2025 for approximately $857,000, including 19,335 shares at a weighted average $9.6391 and 55,000 shares at a weighted average $12.1895. The filing discloses the ownership chain: James Huang owns Panacea Innovation Limited, which controls the GP entities and the funds. No legal proceedings are reported.
Emendamento n. 1 al Schedule 13D indica che un gruppo di entit脿 legate a Panacea insieme a James Huang detiene beneficiariamente 1.712.900 azioni ordinarie di Atara Biotherapeutics, pari al 20,0% delle 7.023.032 azioni in circolazione al 6 agosto 2025. La posizione include 307.900 warrant immediatamente esercitabili ma soggetti a un vincolo contrattuale che ne impedisce l鈥檈sercizio nella misura in cui aumenterebbe la partecipazione oltre il 19,99%, pertanto i warrant non possono essere esercitati attualmente. Panacea Venture Healthcare Fund II, L.P. ha acquistato sul mercato aperto 74.335 azioni dal 17 luglio al 19 agosto 2025 per circa $857.000, incluse 19.335 azioni a prezzo medio ponderato di $9,6391 e 55.000 azioni a prezzo medio ponderato di $12,1895. Il documento rivela la catena di controllo: James Huang 猫 proprietario di Panacea Innovation Limited, che controlla le GP entities e i fondi. Non sono riportate azioni legali in corso.
Enmienda n.潞 1 al Schedule 13D informa que un grupo de entidades vinculadas a Panacea y James Huang poseen beneficiariamente 1.712.900 acciones ordinarias de Atara Biotherapeutics, lo que representa el 20,0% de las 7.023.032 acciones en circulaci贸n a fecha de 6 de agosto de 2025. La posici贸n incluye 307.900 warrants ejercitables de inmediato, pero sujetos a un l铆mite contractual que impide su ejercicio en la medida en que aumente la participaci贸n por encima del 19,99%, por lo que actualmente no pueden ejercerse. Panacea Venture Healthcare Fund II, L.P. compr贸 en mercado abierto 74.335 acciones entre el 17 de julio y el 19 de agosto de 2025 por aproximadamente $857.000, incluidas 19.335 acciones a un precio medio ponderado de $9,6391 y 55.000 acciones a un precio medio ponderado de $12,1895. La presentaci贸n revela la cadena de propiedad: James Huang posee Panacea Innovation Limited, que controla las entidades GP y los fondos. No se informan procedimientos legales.
Schedule 13D 靾橃爼鞎� 1順�電� 韺岆倶鞁滌晞 甏�霠� 旮办梾霌り臣 鞝滌瀯鞀� 頇╈澊 頃╈硱靹� 鞎勴儉霛� 氚旍澊鞓ろ厡霛柬摠韹膘姢 氤错喌欤� 1,712,900欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 8鞗� 6鞚� 旮办 氚滍枆欤检嫕靾� 7,023,032欤�鞚� 20.0%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞚� 氤挫湢鞐愲姅 歃夓嫓 頄夓偓 臧�電ロ暅 307,900瓯挫潣 鞗岆煱韸�臧� 韽暔霅橃柎 鞛堨溂雮�, 氤挫湢 牍勳湪鞚� 19.99% 齑堦臣搿� 歃濌皜鞁滍偆電� 瓴届毎鞐愲姅 頄夓偓臧� 鞝滍暅霅橂姅 瓿勳暯靸� 靸來暅鞚� 鞛堨柎 順勳灛電� 頄夓偓頃� 靾� 鞐嗢姷雼堧嫟. Panacea Venture Healthcare Fund II, L.P.電� 2025雲� 7鞗� 17鞚茧秬韯� 8鞗� 19鞚缄箤歆� 鞛ル偞瓯半灅搿� 74,335欤�毳� 鞎� $857,000鞐� 毵れ瀰頄堨溂氅�, 鞚� 欷� 19,335欤茧姅 臧�欷戫弶攴� $9.6391, 55,000欤茧姅 臧�欷戫弶攴� $12.1895鞐� 毵れ垬頄堨姷雼堧嫟. 鞝滌稖靹滊電� 靻岇湢 甑“毳� 氚濏榾: 鞝滌瀯鞀� 頇╈澊 Panacea Innovation Limited毳� 靻岇湢頃橁碃, 鞚� 須岇偓臧� GP 瓿勳棿靷摛瓿� 韼�霌滊ゼ 韱奠牅頃╇媹雼�. 氩曥爜 靻岇啞鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Avenant n掳1 au Schedule 13D indique qu鈥檜n groupe d鈥檈ntit茅s li茅es 脿 Panacea et James Huang d茅tiennent b茅n茅volement 1 712 900 actions ordinaires d鈥橝tara Biotherapeutics, soit 20,0% des 7 023 032 actions en circulation au 6 ao没t 2025. La position comprend 307 900 bons de souscription imm茅diatement exer莽ables mais soumis 脿 un plafond contractuel emp锚chant leur exercice dans la mesure o霉 il augmenterait la participation au-del脿 de 19,99%, de sorte qu鈥檌ls ne peuvent pas 锚tre exerc茅s pour l鈥檌nstant. Panacea Venture Healthcare Fund II, L.P. a achet茅 en march茅 ouvert 74 335 actions du 17 juillet au 19 ao没t 2025 pour environ 857 000 $, dont 19 335 actions 脿 un prix moyen pond茅r茅 de 9,6391 $ et 55 000 actions 脿 un prix moyen pond茅r茅 de 12,1895 $. le dossier r茅v猫le la cha卯ne de propri茅t茅 : James Huang poss猫de Panacea Innovation Limited, qui contr么le les entit茅s GP et les fonds. Aucune proc茅dure judiciaire n鈥檈st signal茅e.
Nachtrag Nr. 1 zu Schedule 13D berichtet, dass eine Gruppe panacea-naher Gesellschaften und James Huang zusammen wirtschaftlich 1.712.900 Aktien der Atara Biotherapeutics Stammaktien halten, was 20,0% der zum 6. August 2025 ausstehenden 7.023.032 Aktien entspricht. Die Position umfasst 307.900 Warrants, die sofort aus眉bbar sind, jedoch einer vertraglichen Obergrenze unterliegen, die eine Aus眉bung verhindert, soweit sie die Beteiligung 眉ber 19,99% erh枚hen w眉rde; daher k枚nnen die Warrants derzeit nicht ausge眉bt werden. Panacea Venture Healthcare Fund II, L.P. erwarb in Offenen Markttransaktionen vom 17. Juli bis 19. August 2025 74.335 Aktien f眉r etwa $857.000, davon 19.335 Aktien zu einem gewogenen Durchschnittspreis von $9,6391 und 55.000 Aktien zu $12,1895. Die Einreichung legt die Eigent眉merkette offen: James Huang besitzt Panacea Innovation Limited, die die GP-Entit盲ten und die Fonds kontrolliert. Es werden keine Rechtsstreitigkeiten gemeldet.
- Detailed ownership disclosure showing aggregate beneficial ownership of 1,712,900 shares (20.0%).
- Recent open-market purchases of 74,335 shares totaling approximately $857,000, demonstrating accumulation.
- Warrants cannot currently be exercised due to a 19.99% beneficial ownership cap, limiting immediate dilution or increase in stake.
- High ownership concentration (20.0%) under a single affiliated group may raise governance or influence considerations for other shareholders.
Insights
TL;DR Panacea and affiliated entities hold a disclosed 20.0% stake in Atara, with recent open-market purchases totaling 74,335 shares for ~$857k.
The filing documents a material passive equity position representing one-fifth of Atara's outstanding shares. Recent buys were executed across July and August 2025 at weighted average prices of $9.6391 and $12.1895, indicating accumulation via open market purchases rather than a block trade. The position includes 307,900 warrants that are immediately exercisable but effectively restricted by a 19.99% beneficial ownership cap, meaning no warrant exercises are currently permitted. The ownership structure is centralized under James Huang through Cayman entities, which is important for understanding control and voting influence.
TL;DR A single affiliate group reports shared voting/dispositive power over 1,712,900 Atara shares and discloses governance control links to James Huang.
The amendment clarifies beneficial ownership and the chain of control: James Huang is the sole owner of Panacea Innovation Limited, which controls the GP entities for the reporting funds. That centralized ownership and shared voting power over 20.0% of the class are governance-relevant facts for Atara boards and investors evaluating shareholder concentration. The filing includes standard disclaimers of beneficial ownership by affiliated entities but establishes the practical linkage for coordination and potential influence.
Emendamento n. 1 al Schedule 13D indica che un gruppo di entit脿 legate a Panacea insieme a James Huang detiene beneficiariamente 1.712.900 azioni ordinarie di Atara Biotherapeutics, pari al 20,0% delle 7.023.032 azioni in circolazione al 6 agosto 2025. La posizione include 307.900 warrant immediatamente esercitabili ma soggetti a un vincolo contrattuale che ne impedisce l鈥檈sercizio nella misura in cui aumenterebbe la partecipazione oltre il 19,99%, pertanto i warrant non possono essere esercitati attualmente. Panacea Venture Healthcare Fund II, L.P. ha acquistato sul mercato aperto 74.335 azioni dal 17 luglio al 19 agosto 2025 per circa $857.000, incluse 19.335 azioni a prezzo medio ponderato di $9,6391 e 55.000 azioni a prezzo medio ponderato di $12,1895. Il documento rivela la catena di controllo: James Huang 猫 proprietario di Panacea Innovation Limited, che controlla le GP entities e i fondi. Non sono riportate azioni legali in corso.
Enmienda n.潞 1 al Schedule 13D informa que un grupo de entidades vinculadas a Panacea y James Huang poseen beneficiariamente 1.712.900 acciones ordinarias de Atara Biotherapeutics, lo que representa el 20,0% de las 7.023.032 acciones en circulaci贸n a fecha de 6 de agosto de 2025. La posici贸n incluye 307.900 warrants ejercitables de inmediato, pero sujetos a un l铆mite contractual que impide su ejercicio en la medida en que aumente la participaci贸n por encima del 19,99%, por lo que actualmente no pueden ejercerse. Panacea Venture Healthcare Fund II, L.P. compr贸 en mercado abierto 74.335 acciones entre el 17 de julio y el 19 de agosto de 2025 por aproximadamente $857.000, incluidas 19.335 acciones a un precio medio ponderado de $9,6391 y 55.000 acciones a un precio medio ponderado de $12,1895. La presentaci贸n revela la cadena de propiedad: James Huang posee Panacea Innovation Limited, que controla las entidades GP y los fondos. No se informan procedimientos legales.
Schedule 13D 靾橃爼鞎� 1順�電� 韺岆倶鞁滌晞 甏�霠� 旮办梾霌り臣 鞝滌瀯鞀� 頇╈澊 頃╈硱靹� 鞎勴儉霛� 氚旍澊鞓ろ厡霛柬摠韹膘姢 氤错喌欤� 1,712,900欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 8鞗� 6鞚� 旮办 氚滍枆欤检嫕靾� 7,023,032欤�鞚� 20.0%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞚� 氤挫湢鞐愲姅 歃夓嫓 頄夓偓 臧�電ロ暅 307,900瓯挫潣 鞗岆煱韸�臧� 韽暔霅橃柎 鞛堨溂雮�, 氤挫湢 牍勳湪鞚� 19.99% 齑堦臣搿� 歃濌皜鞁滍偆電� 瓴届毎鞐愲姅 頄夓偓臧� 鞝滍暅霅橂姅 瓿勳暯靸� 靸來暅鞚� 鞛堨柎 順勳灛電� 頄夓偓頃� 靾� 鞐嗢姷雼堧嫟. Panacea Venture Healthcare Fund II, L.P.電� 2025雲� 7鞗� 17鞚茧秬韯� 8鞗� 19鞚缄箤歆� 鞛ル偞瓯半灅搿� 74,335欤�毳� 鞎� $857,000鞐� 毵れ瀰頄堨溂氅�, 鞚� 欷� 19,335欤茧姅 臧�欷戫弶攴� $9.6391, 55,000欤茧姅 臧�欷戫弶攴� $12.1895鞐� 毵れ垬頄堨姷雼堧嫟. 鞝滌稖靹滊電� 靻岇湢 甑“毳� 氚濏榾: 鞝滌瀯鞀� 頇╈澊 Panacea Innovation Limited毳� 靻岇湢頃橁碃, 鞚� 須岇偓臧� GP 瓿勳棿靷摛瓿� 韼�霌滊ゼ 韱奠牅頃╇媹雼�. 氩曥爜 靻岇啞鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Avenant n掳1 au Schedule 13D indique qu鈥檜n groupe d鈥檈ntit茅s li茅es 脿 Panacea et James Huang d茅tiennent b茅n茅volement 1 712 900 actions ordinaires d鈥橝tara Biotherapeutics, soit 20,0% des 7 023 032 actions en circulation au 6 ao没t 2025. La position comprend 307 900 bons de souscription imm茅diatement exer莽ables mais soumis 脿 un plafond contractuel emp锚chant leur exercice dans la mesure o霉 il augmenterait la participation au-del脿 de 19,99%, de sorte qu鈥檌ls ne peuvent pas 锚tre exerc茅s pour l鈥檌nstant. Panacea Venture Healthcare Fund II, L.P. a achet茅 en march茅 ouvert 74 335 actions du 17 juillet au 19 ao没t 2025 pour environ 857 000 $, dont 19 335 actions 脿 un prix moyen pond茅r茅 de 9,6391 $ et 55 000 actions 脿 un prix moyen pond茅r茅 de 12,1895 $. le dossier r茅v猫le la cha卯ne de propri茅t茅 : James Huang poss猫de Panacea Innovation Limited, qui contr么le les entit茅s GP et les fonds. Aucune proc茅dure judiciaire n鈥檈st signal茅e.
Nachtrag Nr. 1 zu Schedule 13D berichtet, dass eine Gruppe panacea-naher Gesellschaften und James Huang zusammen wirtschaftlich 1.712.900 Aktien der Atara Biotherapeutics Stammaktien halten, was 20,0% der zum 6. August 2025 ausstehenden 7.023.032 Aktien entspricht. Die Position umfasst 307.900 Warrants, die sofort aus眉bbar sind, jedoch einer vertraglichen Obergrenze unterliegen, die eine Aus眉bung verhindert, soweit sie die Beteiligung 眉ber 19,99% erh枚hen w眉rde; daher k枚nnen die Warrants derzeit nicht ausge眉bt werden. Panacea Venture Healthcare Fund II, L.P. erwarb in Offenen Markttransaktionen vom 17. Juli bis 19. August 2025 74.335 Aktien f眉r etwa $857.000, davon 19.335 Aktien zu einem gewogenen Durchschnittspreis von $9,6391 und 55.000 Aktien zu $12,1895. Die Einreichung legt die Eigent眉merkette offen: James Huang besitzt Panacea Innovation Limited, die die GP-Entit盲ten und die Fonds kontrolliert. Es werden keine Rechtsstreitigkeiten gemeldet.
FAQ
What stake does Panacea report in Atara Biotherapeutics (ATRA)?
Did Panacea make recent purchases of ATRA shares and at what cost?
Are there warrants included in the reported position for ATRA?
Who controls the Panacea reporting group for this ATRA filing?
Were any legal proceedings disclosed in the Schedule 13D/A for ATRA?
